DCM
NERV icon

Delpha Capital Management’s Minerva Neurosciences NERV Stock Holding History

Delpha Capital Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-154
Closed -$7K – 841
2017
Q4 		$7K Buy
+154
New +$7.64K 0.01% 1181

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
IVAV
Index Venture Associates V St. Helier, Channel Islands, Jersey $1.46M AUM 88.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Delpha Capital Management's NERV Position: Q1 2018 in Review

Delpha Capital Management sold out of Minerva Neurosciences (NERV) in Q1 2018, closing a stake of 154 shares — an estimated $7K sold.

Delpha Capital Management first reported a position in NERV in Q4 2017 and held it in 1 quarter. The position peaked at $7K in Q4 2017. 67 funds tracked by Wall St. Rank hold NERV as of Q1 2018.

  • Delpha Capital Management reported no remaining Minerva Neurosciences position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 154 Minerva Neurosciences shares in Q1 2018, an estimated $7K.
  • Delpha Capital Management first reported a position in Minerva Neurosciences in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Minerva Neurosciences position peaked at $7K in Q4 2017.
  • 67 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.